These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26579371)

  • 21. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
    Chen Z; Shi T; Zhang L; Zhu P; Deng M; Huang C; Hu T; Jiang L; Li J
    Cancer Lett; 2016 Jan; 370(1):153-64. PubMed ID: 26499806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
    Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
    Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apical ABC transporters and cancer chemotherapeutic drug disposition.
    Durmus S; Hendrikx JJ; Schinkel AH
    Adv Cancer Res; 2015; 125():1-41. PubMed ID: 25640265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors.
    Goebel J; Chmielewski J; Hrycyna CA
    Cancer Drug Resist; 2021; 4(4):784-804. PubMed ID: 34993424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
    Gianì F; Russo G; Pennisi M; Sciacca L; Frasca F; Pappalardo F
    Bioinformatics; 2019 Jul; 35(13):2267-2275. PubMed ID: 30481266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
    Wang XK; Fu LW
    Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
    Leslie EM; Deeley RG; Cole SP
    Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of ABC transporters in drug resistance, metabolism and toxicity.
    Glavinas H; Krajcsi P; Cserepes J; Sarkadi B
    Curr Drug Deliv; 2004 Jan; 1(1):27-42. PubMed ID: 16305368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug resistance mediated by ABC transporters].
    Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.